Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Morel

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
NPJ Parkinson'S Disease|October 17, 2025
Optimizing the MDS-UPDRS Part III for early-stage Parkinson's: early supportive evidence for a limb-related bradykinesia/rigidity sub-scoreAntoine Regnault, Maria Key Prato, Stéphane Quéré, et al.
Basic & Clinical Pharmacology & Toxicology|June 2, 2023
Use of deprescribing search filters in systematic review search strategies: A case studyThomas Morel, Clara H Heinrich, Lorène Zerah, et al.
Neurology and Therapy|May 13, 2025
Understanding the Patient Experience of Advanced Parkinson's Disease: Qualitative Research with Patients and Expert Clinicians to Identify Symptoms and Associated Health-Related Quality of Life ImpactsNicola Williamson, Thomas Morel, Helena Bradley, et al.
Orphanet Journal of Rare Diseases|October 31, 2021
Development of the Myasthenia Gravis (MG) Symptoms PRO: a case study of a patient-centred outcome measure in rare diseaseSophie Cleanthous, Ann-Christin Mork, Antoine Regnault, et al.
Trials|November 20, 2014
Publication practices and standards: recommendations from GSK Vaccines' author surveyIsabelle Camby, Véronique Delpire, Laurence Rouxhet, et al.
BMC Infectious Diseases|December 14, 2020
Hormographiella aspergillata: an emerging basidiomycete in the clinical setting? A case report and literature reviewMaxime Moniot, Rose-Anne Lavergne, Thomas Morel, et al.
Orphanet Journal of Rare Diseases|February 18, 2017
Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012Kim Pauwels, Isabelle Huys, Minne Casteels, et al.
Orphanet Journal of Rare Diseases|December 25, 2013
Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countriesThomas Morel, Francis Arickx, Gustaf Befrits, et al.
Neurology and Therapy|May 11, 2023
Measuring Overall Severity of Myasthenia Gravis (MG): Evidence for the Added Value of the MG Symptoms PROAntoine Regnault, Thomas Morel, Christine de la Loge, et al.
The Patient|October 10, 2022
Improving Interpretation of Evidence Relating to Quality of Life in Health Technology Assessments of Rare Disease TreatmentsElena Nicod, Andrew J Lloyd, Thomas Morel, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
NPJ Parkinson'S Disease|October 17, 2025
Optimizing the MDS-UPDRS Part III for early-stage Parkinson's: early supportive evidence for a limb-related bradykinesia/rigidity sub-scoreAntoine Regnault, Maria Key Prato, Stéphane Quéré, et al.
Basic & Clinical Pharmacology & Toxicology|June 2, 2023
Use of deprescribing search filters in systematic review search strategies: A case studyThomas Morel, Clara H Heinrich, Lorène Zerah, et al.
Neurology and Therapy|May 13, 2025
Understanding the Patient Experience of Advanced Parkinson's Disease: Qualitative Research with Patients and Expert Clinicians to Identify Symptoms and Associated Health-Related Quality of Life ImpactsNicola Williamson, Thomas Morel, Helena Bradley, et al.
Orphanet Journal of Rare Diseases|October 31, 2021
Development of the Myasthenia Gravis (MG) Symptoms PRO: a case study of a patient-centred outcome measure in rare diseaseSophie Cleanthous, Ann-Christin Mork, Antoine Regnault, et al.
Trials|November 20, 2014
Publication practices and standards: recommendations from GSK Vaccines' author surveyIsabelle Camby, Véronique Delpire, Laurence Rouxhet, et al.
BMC Infectious Diseases|December 14, 2020
Hormographiella aspergillata: an emerging basidiomycete in the clinical setting? A case report and literature reviewMaxime Moniot, Rose-Anne Lavergne, Thomas Morel, et al.
Orphanet Journal of Rare Diseases|February 18, 2017
Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012Kim Pauwels, Isabelle Huys, Minne Casteels, et al.
Orphanet Journal of Rare Diseases|December 25, 2013
Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countriesThomas Morel, Francis Arickx, Gustaf Befrits, et al.
Neurology and Therapy|May 11, 2023
Measuring Overall Severity of Myasthenia Gravis (MG): Evidence for the Added Value of the MG Symptoms PROAntoine Regnault, Thomas Morel, Christine de la Loge, et al.
The Patient|October 10, 2022
Improving Interpretation of Evidence Relating to Quality of Life in Health Technology Assessments of Rare Disease TreatmentsElena Nicod, Andrew J Lloyd, Thomas Morel, et al.
Pageof 6